BioLineRx (NASDAQ:BLRX) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a report issued on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of BioLineRx in a research report on Wednesday, November 6th.

BioLineRx Stock Down 14.0 %

Shares of NASDAQ BLRX opened at $0.28 on Friday. The stock has a market capitalization of $22.23 million, a P/E ratio of -0.62 and a beta of 1.48. The stock’s fifty day moving average is $0.49 and its 200 day moving average is $0.61. BioLineRx has a 52 week low of $0.26 and a 52 week high of $1.89. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61.

Institutional Trading of BioLineRx

Institutional investors and hedge funds have recently bought and sold shares of the stock. CVI Holdings LLC bought a new position in shares of BioLineRx during the second quarter worth about $462,000. Atria Investments Inc increased its position in BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares during the period. Finally, PVG Asset Management Corp bought a new position in BioLineRx during the 2nd quarter worth approximately $70,000. 1.56% of the stock is currently owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.